Crizotinib Capsules Suppliers & Bulk Manufacturers
Available Forms: Oral Capsules
Available Strengths: 200 mg, 250 mg
Reference Brands: Xalkori® (US & EU)
Category:
Oncology Cancer Care
Crizotinib Capsules are used to treat ALK-positive NSCLC and ROS1-positive cancers, as well as anaplastic large cell lymphoma (ALCL). As a tyrosine kinase inhibitor (TKI), it blocks cancer-causing proteins. Available as Xalkori® in 200 mg and 250 mg strengths, Crizotinib is manufactured under GMP standards, making it a trusted option for oncology treatment in US and EU markets.
Crizotinib Capsules is available in Oral Capsules
and strengths such as 200 mg, 250 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Crizotinib Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Crizotinib Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Crizotinib Capsules are a targeted therapy used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) and ROS1-positive cancers, as well as anaplastic large cell lymphoma (ALCL). As a tyrosine kinase inhibitor (TKI), Crizotinib blocks the activity of abnormal proteins responsible for cancer cell growth. Marketed under Xalkori®, Crizotinib is available in 200 mg and 250 mg oral capsule strengths. Manufactured under GMP-compliant conditions, it offers a reliable solution for pharmaceutical distributors targeting US and EU oncology markets, providing effective treatment options for precision cancer medicine.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing